ChiCTR2000040018: Phase the Safety and Tolerability of CD19 Universal Chimeric Antigen Receptor T Cells in Subjects with R/R CD19 positive B cell malignant tumors |
|
|
| Not yet recruiting | 1 | 12 | | Infusion 3 dose levels: 0.5x10^6 cells/kg, 1.0x10^6 cells/kg, 2.0x10^6 cells/kg ;Infusion 3 dose levels: 2.0x10^6 cells/kg, 3.0x10^6 cells/kg, 5.0x10^6 cells/kg ;Infusion 3 dose levels: 3.0x10^6 cells/kg, 5.0x10^6 cells/kg, 7.0x10^6 cells/kg ;Select the above optimal dose for a single dose | The Affiliated Hospital of Nantong University; The Affiliated Hospital of Nantong University, Suzhou Maximum Bio-tech Co., Ltd. | R/R CD19-positive B-cell Malignant Tumors | | | | |
ChiCTR2000039849: To evaluate the safety and tolerability of CD19 UCAR-T cell injection in subjects with recurrent/refractory CD19 positive B cell malignancies |
|
|
| Recruiting | N/A | 12 | | 0.5×10^6 UCAR+ T Cells/kg; 1.0×10^6 UCAR+ T Cells/kg ;2.0×10^6 UCAR+ T Cells/kg | Zhongshan People's Hospital; Zhongshan People's Hospital, Suzhou Maximum Bio-tech Co., Ltd | Relapsed/refractory CD19-positive B-cell malignancies | | | | |